Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small interfering RNA |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
M09AX10
|
| gptkbp:brand |
gptkb:Oxlumo
|
| gptkbp:CASNumber |
2100172-34-6
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
lumasiran
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits glycolate oxidase
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
gptkb:hydroxyacid_oxidase_1_(HAO1)_mRNA
|
| gptkbp:usedFor |
gptkb:primary_hyperoxaluria_type_1
|
| gptkbp:bfsParent |
gptkb:Oxlumo
|
| gptkbp:bfsLayer |
7
|